ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dulaglutide

Also written as “Dulaglutide”, “LY2189265” and “Dulaglutide (Reference)”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 3 companies.

Drug pageDulaglutide: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 21, 201647 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly451 open or runningphase 4since Apr 21, 2016Feb 28, 2008Dec 2027phase 3 · NCT06739122
CSPC Pharmaceutical Groupits history only10 open or runningphase 3since Jan 23, 2024Jan 23, 2024none ahead
Innovent Biologicsits history only10 open or runningphase 3since Oct 19, 2022Oct 19, 2022none ahead

Also a collaborator on its studies: United BioSource and Tessella.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 30 studies since Feb 28, 2008.

  1. Nov 3, 2015Phase 3 study in Diabetes Mellitus, Type 2NCT02597049 · 424 enrolled · United States, Austria, Czechia and more
  2. Apr 21, 2016Phase 4 study in Diabetes Mellitus, Type 2NCT02750410 · 159 enrolled · Japan
  3. Nov 10, 2016Phase 3 study in Diabetes Mellitus, Type 2NCT02963766 · 154 enrolled · United States, Brazil, France and more
  4. Nov 22, 2016Phase 2 study in Diabetes Mellitus, Type 2NCT02973100 · 318 enrolled · United States, Czechia, Mexico and more
  5. Oct 17, 2017Phase 4 study in Diabetes Mellitus, Type 2NCT03315780 · 12 enrolled · Japan
  6. Dec 1, 2017Phase 1 study in HealthyNCT03363906 · 27 enrolled · United States
  7. Apr 2, 2018Phase 3 study in Diabetes Mellitus, Type 2NCT03495102 · 1,842 enrolled · United States, Argentina, Austria and more
  8. Oct 16, 2020Phase 3 study in Diabetes Mellitus, Type 2NCT04591626 · 291 enrolled · China
  9. Nov 20, 2020Phase 1 study in Diabetes Mellitus, Type 2NCT04641312 · 67 enrolled · Germany
  10. Mar 19, 2021Phase 3 study in Diabetes MellitusNCT04809220 · 591 enrolled · Japan
  11. May 16, 20222 phase 1 studies in Diabetes Mellitus, Type 2NCT05377333, NCT05407961
  12. Dec 15, 2022Phase 4 study in Diabetes Mellitus, Type 2NCT05659537 · 212 enrolled · India
  13. Dec 13, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06739122 · 55 planned · United States, Argentina, Mexico
  14. Dec 18, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07313813 · 20 enrolled · Singapore

Ahead

  1. Dec 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT06739122

TargetBeta

GLP1R →read by rule
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently ”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 45 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07313813Diabetes Mellitus, Type 2 · Singapore1CompletedAug 13, 202620
NCT06739122Diabetes Mellitus, Type 2 · United States, Argentina, Mexico3RecruitingDec 202755
NCT05659537Diabetes Mellitus, Type 2 · India4CompletedJan 16, 2024212
NCT05407961Diabetes Mellitus, Type 2 · Germany1CompletedJan 12, 202490
NCT05377333Diabetes Mellitus, Type 2 · United States1CompletedNov 22, 202394
NCT04809220Diabetes Mellitus · Japan3CompletedOct 1, 2022591
NCT04641312Diabetes Mellitus, Type 2 · Germany1CompletedDec 21, 202167
NCT04591626Diabetes Mellitus, Type 2 · China3CompletedApr 28, 2022291
NCT03495102Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more3CompletedMay 28, 20191,842
NCT03363906Healthy · United States1CompletedJun 6, 201827
NCT03315780Diabetes Mellitus, Type 2 · Japan4CompletedFeb 28, 201812
NCT02973100Diabetes Mellitus, Type 2 · United States, Czechia, Mexico and more2CompletedJul 15, 2017318
NCT02963766Diabetes Mellitus, Type 2 · United States, Brazil, France and more3CompletedJun 12, 2021154
NCT02750410Diabetes Mellitus, Type 2 · Japan4CompletedJun 18, 2018159
NCT02597049Diabetes Mellitus, Type 2 · United States, Austria, Czechia and more3CompletedFeb 2017424
NCT02152371Diabetes Mellitus, Type 2 · United States, Czechia, Hungary and more3CompletedOct 2015300
NCT01769378Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more3CompletedDec 2014300
NCT01667900Diabetes Mellitus, Type 2 · China1CompletedJun 201458
NCT01644500Diabetes Mellitus, Type 2 · China, Korea, Republic of, Taiwan3CompletedAug 2014737
NCT01648582Diabetes Mellitus, Type 2 · China, Korea, Republic of, Mexico and more3CompletedAug 2014774
NCT01624259Diabetes Mellitus, Type 2 · United States, Czech Republic, Germany and more3CompletedNov 2013599
NCT01621178Diabetes Mellitus, Type 2 · United States, Brazil, Hungary and more3CompletedJun 2016577
NCT01584232Diabetes Mellitus, Type 2 · Japan3CompletedJul 2013361
NCT01558271Diabetes Mellitus, Type 2 · Japan3CompletedOct 2013492
NCT01524770Diabetes Mellitus, Type 2 · United States1CompletedJun 201250
NCT01458210Diabetes Mellitus, Type 2 · United States1CompletedFeb 201222
NCT01436201Diabetes Mellitus, Type 2 · United States1CompletedNov 201124
NCT01432938Diabetes Mellitus, Type 2 · United States1CompletedDec 201128
NCT01408888Diabetes Mellitus, Type 2 · United States1CompletedApr 201229
NCT01394952Cardiovascular Diseases · United States, Argentina, Australia and more3CompletedAug 21, 20189,901
NCT01324388Diabetes Mellitus, Type 2 · United States1CompletedAug 201151
NCT01301092Diabetes Mellitus, Type 2 · United States1CompletedAug 201130
NCT01300260Diabetes Mellitus, Type 2 · Germany1CompletedAug 201132
NCT01253304Diabetes Mellitus, Type 2 · Germany, Hungary1CompletedNov 201126
NCT01250834Healthy Volunteers · United Kingdom1CompletedMar 201127
NCT01215968Diabetes Mellitus, Type 2 · United Kingdom1CompletedJul 201138
NCT01191268Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedFeb 2012884
NCT01149421Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more2CompletedSep 2011755
NCT01126580Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3CompletedNov 2011807
NCT01075282Diabetes Mellitus, Type 2 · Argentina, Australia, Belgium and more3CompletedMay 2012810
NCT01064687Diabetes Mellitus, Type 2 · United States, Argentina, Mexico and more3CompletedNov 2011978
NCT01001104Diabetes Mellitus, Type 2 · Japan2CompletedDec 2010145
NCT00791479Diabetes Mellitus, Type 2 · United States, Croatia, Denmark and more2CompletedJan 2010167
NCT00734474Diabetes Mellitus, Type 2 · United States, Canada, France and more3CompletedJun 20111,202
NCT00630825Diabetes Mellitus, Type 2 · United States, Puerto Rico2CompletedJan 2009262

How it is read

Names in the registry

  • “Dulaglutide”, 25 entries
  • “LY2189265”, 18 entries
  • “dulaglutide”, 2 entries
  • “Dulaglutide (Reference)”, 1 entry
  • “Dulaglutide (Test)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.